BI-505
by Jessica Langholtz
Published: Oct 2, 2010 10:55 pm
Published: Oct 2, 2010 10:55 pm
| Brand Name: | |
| Generic Name: | |
| Code Name: | BI-505 |
| Company: | BioInvent |
| FDA Clinical Phase: | 1 |
Description:
BI-505 is a fully human antibody that causes cell death. It binds to the protein ICAM-1 (CD54), which is more common in tumors than in normal tissue. BI-505 may therefore be used to kill cancerous cells that have ICAM-1, including multiple myeloma cells. The FDA approved Phase 1 clinical trials for BI-505 in 2009, and the studies began in January 2010.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for BI-505: http://www.bioinvent.com/products/pipeline/bi-505
Related Articles:
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
